Over the last 15 years, the Los Alamos Immunology Database has posted regularly updated lists of best-characterized HIV-1 CTL epitopes (A-list). Here we provide an extensive overhaul of the A-list, applying expanded inclusion criteria that reflect new technologies and progress in the field. A few previously included, incorrect epitopes were removed or amended, and more than 35 newly identified epitopes were added. This updated A-list expands the number of well-described, fine-mapped and HLA class I restricted epitopes to more than 300, presented across more than 80 different HLA class I alleles. A number of considerations for optimal epitope mapping and for the assessment and interpretation of host immunity to HIV are discussed.
I-A-1 Introduction
Since the first description of HIV-specific T-cell responses 25 years ago by Walker et al. [1987] , much has been learned about their in vivo induction, anti-viral activity, and role in HIV control. Combined studies of host genetic factors, viral sequence polymorphisms, viral fitness data and the fine mapping of virus-specific T-cell responses strongly suggest that the specificity of cytotoxic T-lymphocyte (CTL) responses and their HLA restriction are crucial determinants for viral control [Kiepiela et al., 2007; Mothe et al., 2011; Zuñiga et al., 2006] . Data from in vitro viral replication inhibition assays show that CTL clones targeting Gag clearly outperformed other specificities, in particular, CTL targeting envelope proteins [Chen et al., 2009 [Chen et al., , 2011 , and may relate to the loss in replicative fitness when the virus has to escape from T-cell specificities to relatively conserved epitopes [Brockman et al., 2012; Ferrari et al., 2011; Troyer et al., 2009] . In addition, CTL responses associated with relative protection from HIV disease progression have an increased functional avidity and a superior ability to react with epitope variants [Berger et al., 2011; . Interestingly, some of these studies employed CTL epitopes that can be restricted by HLA alleles associated with both slower and faster HIV disease progression, suggesting that the restricting HLA alleles can severely impact the in vivo "quality" of CTL responses [Frahm et al., 2007; Leslie et al., 2006] . Evidently, most of these studies rely heavily on the unequivocal identification of the targeted epitopes and their restricting HLA class I allele. The collection of such well-defined epitopes has been the central aim of our efforts to create and maintain a list of optimally defined epitopes at the Los Alamos HIV database, for which we here provide the 2013 update.
I-A-2 History and development of the CTL epitope A-list
Since 1995, we have maintained a list of the bestcharacterized HIV-derived CTL epitopes at the Los Alamos National Laboratory HIV Immunology Database, often referred to as the "Optimal CTL Epitope List" or "A-list" of HIV CTL epitopes. From an original set of 60 epitopes restricted by 20 (2-digit) HLA class I alleles in 1995, this list has grown to over 270 epitopes restricted by 21 different HLA-A (86 epitopes), 46 HLA-B (161 epitopes) and 15 HLA-C (25 epitopes) alleles in 2012. The present update adds an additional 41 epitopes to this list (7 on HLA-A, 29 on HLA-B and 5 on HLA-C alleles with many restricted by traditionally understudied HLA class I alleles. The importance of defining the restricting HLA allele at a 4 digit resolution is highlighted in a number of recent studies that show that the presented epitope repertoires can vary widely even between closely related HLA class I alleles [Kloverpris et al., 2012a,b] . This is especially marked for the HLA-B15 serotype and its subtypes [Frahm et al., 2005 [Frahm et al., , 2006 , but is also relevant for other serotypes, for instance HLA-A68, where subtypes fall into different HLA supertypes (A*6801 in A3, A*6802 in A2) and have vastly different HLA binding motifs [Sidney et al., 2008] .
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HLA restriction
Based on technical advances in detecting epitope-specific immune response, data on structural characteristics of epitope/HLA complexes and the increasing reliability of known allele-specific binding motifs, we have revised our criteria for inclusion of epitopes in the current issue of the CTL epitopes A-list. Initially, restriction analyses using partly HLA-matched antigen presenting cells covering all 6 classical HLA class I alleles were considered the goldstandard for inclusion of epitopes, owing to the fact that conflicting data were obtained when studying widely promiscuous epitopes. In addition, in early reports, HLA-C alleles were often not typed and not controlled for in restriction analyses. With the improved understanding of the promiscuous nature of CTL epitopes [Frahm et al., 2007] , revised definitions of HLA supertypes [Sidney et al., 2008] , and the availability of cell lines expressing a single HLA allele, this inclusion criterion is now relaxed. Furthermore, with the advent of tetramer and related technology, the need for extensive cellular HLA-mismatch analyses has been further reduced. As a consequence, the most recent updates of this A-list have increasingly included epitopes for which HLA restriction had been demonstrated by any of the following approaches: single allele expressing cell lines, tetramers, and the older technology of using HLAmismatched antigen presenting cells, or by inference of peptide binding motifs from closely related HLA alleles. However, we still exclude the predicted HLA restrictions based on large-cohort screenings in which individuals with a matching peptide-specific response share a single, presumably restricting, HLA allele [Kiepiela et al., 2004] . The main reason not to accept such HLA restriction information for the present listing is that it is not uncommon that the emerging alleles are expressed in strong linkage disequilibrium with additional allele(s), making it necessary to experimentally identify the actual restricting allele. While in cases of overwhelming statistical significance (e.g., p < 10 −26 , [Ngumbela et al., 2008] ) the predicted HLA would quite likely be correct, it would be problematic to define a cut-off at which a statistically-inferred HLA restriction would be considered sufficient.
Optimal epitope length
When we collected epitopes for the very first A-list of optimal CTL epitopes, we focused strongly on defining an optimal epitope length, which was defined as the shortest peptide eliciting the maximal response. As a consequence, the epitopes that have been included over the years likely reflect more a listing of "minimal" epitopes, not in all cases being the same as the most potent epitope or the one that actually gets presented upon natural antigen processing. This may have led to shorter epitopes being over-represented in the present listing, at the cost of extended epitope variants.
In light of a number of reports showing the existence of longer and bulged epitopes presented by many HLA class I alleles [Burrows et al., 2006; Tenzer et al., 2009] , we have now revised our inclusion criteria for new epitopes to be included. For the present update, we have re-examined all epitope entries in the "B-list" of the immunology database (i.e., all reports describing specific T-cell targets in the HIV proteome since 1991) that were of up to 14 amino acids in length for potential well-defined epitopes fulfilling the revised criteria. We have thereby also paid special attention to more recent reports that complement original studies that included incompletely characterized epitopes. This is, for instance, the case where older papers did not include a full set of well-designed peptide truncations, but more recent reports completed them. In some of these cases, we have used published data on escape mutation analyses that cover mutations within and outside the putative optimal epitope. If mutations impact the in vitro recognition of the epitopes by specific T cells, it is quite conceivable that the mutation is located within the presented epitope and will reveal the true epitope length, unless the tested variant represents a processing escape mutation. Furthermore, in most cases, titration analyses show marked differences between serially truncated epitope versions, allowing a correct definition of the necessary N-and C-terminal residues.
Conflicting results between laboratories
From our review of the literature, truncation of one amino acid at the N-terminus often conserves CTL recognition, which can evidently lead to a conflicting definition of the optimal epitope length. There are many examples of this, such as the (D)YVDRFFKTL epitope restricted by HLACw*0304 [Kiepiela et al., 2004] or the HLA-Cw*0801 restricted Nef epitope (K)AAVDLSHFL. Such shorter embedded epitopes could still fit the necessary binding requirements for the presenting allele, while other cases may clash with described anchor motifs and indicate that one or the other epitope is likely the naturally produced and presented one. One such example is the well-described HLA-A11 epitope (A)CQGVGGPGHK in Gag-p24 [Sipsas et al., 1997] . The originally reported epitope contains an alanine residue at the N-terminus, making the cysteine the unlikely anchor position for the B-pocket of HLA-A11. Indeed, a more recent report described the optimal epitope as the 10-mer CQGVGGPGHK, although without conducting any truncation analyses [Gong et al., 2006] . Yet, the 10-mer fits the motif with Q in the second position and was used to form highly stable tetramers, strongly suggesting that this is the naturally presented epitope (although truncated versions of original 11-mer epitopes can still form stable tetramers [Propato et al., 2001] From the exhaustive re-examination of the literature that we conducted for this update, it is clear that there are many more already-described epitopes that are quite likely representing "optimal" epitopes, but do not satisfy some of the above criteria. Among these are epitopes identified by binding motif prediction approaches. However, as the present list of experimentally defined epitopes can also serve as training set for binding motif prediction algorithms, we specifically exclude epitopes solely defined based on HLA allele-specific motif predictions, as this would cause the prediction algorithms to be fed with predicted motif information, which tends to return predominantly shorter epitopes [Burrows et al., 2006] .
I-A-4 Summary
Careful definition of optimal epitopes can have far reaching consequences for HIV vaccine selection, measurement of host immunity to natural infection, and interpretation of HIV evolution in response to host immune control. The 2013 update of the Los Alamos HIV Immunology Database CTL epitope A-list expands the number of welldescribed, experimentally fine-mapped and HLA class I restricted epitopes to more than 300, presented across more than 80 different HLA class I alleles. With the increased description of extended and embedded epitopes, however, there is also be a chance that conflicting information on epitope length and HLA restrictions will emerge from different laboratories. We would like to encourage everyone in the field to please communicate these instances, as well as any other gross or less evident mistakes that may still exist in the current listing, so we can correct and annotate listed epitopes accordingly. We again thank all investigators who have contributed to the current listing with unpublished data, suggestions, and questions, which have helped make this listing increasingly useful and accurate.
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The location and HLA restriction elements of CTL epitopes are indicated on protein sequences of HXB2. These maps are meant to provide the relative location of defined epitopes on a given protein, but the HXB2 sequence may not actually carry the epitope of interest, as it may vary relative to the sequence for which the epitope was defined. [ Buseyne, 1999] 
